Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011 [0.03%]
2004年至2011年匹配的同种异体干细胞移植程序的结果
Natasha Ali,Salman Naseem Adil,Mohammad Usman Shaikh et al.
Natasha Ali et al.
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders. All patients with non-malignant and malignant haematological disorders with HL...
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma [0.03%]
伊匹单抗治疗转移性黑色素瘤后出现严重的中性粒细胞减少伴大颗粒淋巴细胞增多症病例报告
Guoqing Wei,Uzoma Nwakuche,Gustavo Cadavid et al.
Guoqing Wei et al.
Expansion of hematopoietic stem cells for transplantation: current perspectives [0.03%]
造血干细胞移植的扩增：当前的观点
Jessica A Schuster,Maria R Stupnikov,Gina Ma et al.
Jessica A Schuster et al.
Hematopoietic stem cells (HSCs) are rare cells that have the unique ability to self-renew and differentiate into cells of all hematopoietic lineages. The expansion of HSCs has remained an important goal to develop advanced cell therapies fo...
Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation [0.03%]
尼洛替尼和移植物抗白血病效应诱导的Ph+急性淋巴细胞白血病移植后遗传学复发患者的持续分子学缓解
Paul Farnsworth,David Ward,Vijay Reddy
Paul Farnsworth
We report the successful treatment and sustained molecular remission using single agent nilotinib in a relapsed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplanta...
Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety [0.03%]
细胞因子诱导的杀伤(CIK)细胞治疗肝细胞癌的疗效和安全性分析
Yue Ma,Ying-Chun Xu,Lei Tang et al.
Yue Ma et al.
Purpose: To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma. Materials and methods: ...
Kayo Harada,Kazuhiko Ikeda,Hayato Matsumoto et al.
Kayo Harada et al.
Chronic lymphocytic leukemia (CLL) rarely exhibits an aggressive clinical course and its patients often have chromosomal deletions or additions. Furthermore, reciprocal translocations are barely observed in CLL. There have only been a few r...
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis [0.03%]
脂质体多柔比星与传统蒽环类药物安全性及毒性的比较：meta分析
Shamudheen M Rafiyath,Mohammad Rasul,Byung Lee et al.
Shamudheen M Rafiyath et al.
Background: Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyc...
Publish, not perish: Introducing Experimental Hematology & Oncology [0.03%]
发表，不失落：Experimental Hematology & Oncology期刊介绍
Zihai Li,Chung-Tsen Hsueh,Delong Liu
Zihai Li
As a scientific discipline, medicine can only be advanced by experimentation. Experimentation could either validate or refute a hypothesis. Unfortunately, today's publication climate strongly favors publication of positive research findings...
Thalidomide and its analogues in the treatment of Multiple Myeloma [0.03%]
治疗多发性骨髓瘤的thalidomide及其类似物
Tahir Latif,Nabeel Chauhan,Rashid Khan et al.
Tahir Latif et al.
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positi...
Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation [0.03%]
补体抑制剂依库珠单抗治疗凝血抑制治疗无效的阵发性夜间血红蛋白尿症合并毕肖普法布里西综合征患者
Andrés Brodsky,Octavio Mazzocchi,Fabiana Sánchez et al.
Andrés Brodsky et al.
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, life-threatening disorder characterized by chronic intravascular hemolysis caused by uncontrolled complement activation. Hepatic vein thrombosis (Budd-Chiari syndrome) is common in...